A groundbreaking study, recently published in the prestigious journal *Nature*, introduces a novel intratumoral vaccination strategy that holds significant promise for revolutionizing cancer treatment. Developed by a team of scientists, this innovative approach utilizes a specially engineered molecule termed iVAC (intratumoral vaccination chimera). iVAC functions uniquely by simultaneously acting as a targeted protein degrader and a cancer vaccine. The core mechanism involves reprogramming tumor cells within the tumor microenvironment to perform two critical tasks. Firstly, iVAC degrades immune checkpoint proteins such as PD-L1, which cancer cells often express to evade immune detection, effectively disarming the tumor's defenses. Secondly, it compels these tumor cells to process and present their own cancer-specific antigens to the immune system. This process essentially transforms the tumor cells into antigen-presenting cells (APC-like tumor cells), thereby stimulating a potent and localized anti-tumor immune response. This dual-action mechanism not only alleviates immune suppression but also actively promotes the body's ability to recognize and attack cancer cells, offering a significant advancement over traditional immunotherapies. While the research, which originated from labs including Shenzhen Bay Laboratory, highlights the potential of this strategy to overcome barriers posed by immune suppression and promote durable tumor-specific immunity, further studies are necessary to evaluate its efficacy and safety in clinical settings. This scientific achievement represents a significant stride in the global fight against cancer and expands the rapidly evolving field of targeted protein degradation in immunotherapy.